California CRE News In Your Inbox.
Sign up for Connect emails to stay informed with CRE stories that are 150 words or less.
Xaira Therapeutics Expands Space with BioMed Realty
BioMed Realty, a Blackstone portfolio company, said Wednesday it had executed a lease amendment with Xaira Therapeutics, a leading AI-driven drug discovery company. Xaira Therapeutics is expanding its headquarters from its current 56,233-square-foot space at BioMed Realty’s Gateway of Pacific III campus, located at 700 Gateway Blvd. in South San Francisco, to a total of 73,075 square feet at the same location.
The expansion reflects growing demand for Class A life science facilities in the Bay Area and supports Xaira’s rapid growth as a leader in AI-driven drug discovery, according to BioMed. The space will serve as a foundation for advancing Xaira’s machine-learning research and therapeutic product development, reinforcing the Bay Area’s status as a global hub for biotech and technology innovation.
“Xaira’s new facility at BioMed Realty’s Gateway of Pacific III campus creates a collaborative and inviting space to focus on critical work that has the potential to reshape the drug development landscape through the use of AI,” said Uplaksh Kumar of Xaira.
